Clinical trial
A Phase 2 Study of Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
NCT05509595 is registered in ClinicalTrials.gov with National Institute of Dental and Craniofacial Research (NIDCR) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 7, 2022
- Completion date
- November 18, 2024
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.